Neurophysiology of Melanopsin Photoreceptors
- Institution
- BOSTON CHILDREN'S HOSPITAL, MA
- Principal investigator
- Michael Tri Hoang Do
- Funding
- $506K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY Intrinsically photosensitive retinal ganglion cells (ipRGCs) are neurons of the mammalian eye that capture light with a molecule called melanopsin, triggering a phototransduction cascade to generate an electrical response. This response influences dozens of brain regions and is essential for light’s normal regulation of processes that include the circadian clock, sleep, mood, and pupil constriction. Our preliminary experiments reveal ipRGC response features that are suited to these processes and qualitatively distinct from those of the classic rod and cone photoreceptors. We propose to characterize these response features, learn how they arise from molecular mechanisms within ipRGCs, and define how they shape signals sent from ipRGCs to the brain. We will apply patch-clamp electrophysiological recording to the ex vivo mouse retina and its isolated cells, introducing methods that increase the physiological relevance of our findings. Our experiments will strengthen the basic understanding of ipRGCs, sensory transduction, and ion channels. They will also provide insight into the broad question of how cells of particular types are tailored to specific tasks.
LOADING MOONBASE SCORE
Questions for BOSTON CHILDREN'S HOSPITAL
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Boston Children'S HospitalNot yet scored
Signal Generation and Processing in the Retinohypothalamic Pathway
Michael Tri Hoang Do · $701K · 2024–2029
- NIH · Boston Children'S HospitalNot yet scored
Downstream Actions of Biophysical Mechanisms in the Visual System
Michael Tri Hoang Do · $509K · 2022–2027
- NIH · Boston Children'S Hospital67
A 90 day, Phase 3, Open Labeled Exploratory Study of RELiZORB to Evaluate Safety, Tolerability, and Nutrient Absorption in Children with Short Bowel Syndrome who are Dependent on Parenteral Nutrition
Mark Puder · $365K · 2021–2028